NovoCure (NVCR) Free Cash Flow Growth (1y) (2015 - 2026)
NovoCure (NVCR) Free Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -14.34% |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn | 105.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105.68% |
| Mar 31, 2026 | 59.66% |
| Dec 31, 2025 | -84.78% |
| Sep 30, 2025 | 4,959.61% |
| Jun 30, 2025 | -62.71% |
| Mar 31, 2025 | -6.73% |
| Dec 31, 2024 | 42.03% |
| Sep 30, 2024 | 98.84% |
| Jun 30, 2024 | 55.62% |
| Mar 31, 2024 | -90.04% |
| Dec 31, 2023 | -110.88% |
| Sep 30, 2023 | -258.92% |
| Jun 30, 2023 | -355.08% |
| Mar 31, 2023 | -159.85% |
| Dec 31, 2022 | -7,898.46% |
| Sep 30, 2022 | -20.78% |
| Jun 30, 2022 | -50.62% |
| Mar 31, 2022 | -163.63% |
| Dec 31, 2021 | -99.73% |
| Sep 30, 2021 | -18.19% |